Maria Laura Canale1, Andrea Camerini2, Alda Huqi3, Alessio Lilli3, Irma Bisceglia4, Iris Parrini5, Chiara Lestuzzi6, Jacopo Del Meglio3, Sara Donati2, Elio Venturini7, Alessandro Sgambato8, Luigi Tarantini9, Domenico Amoroso2, Giancarlo Casolo3. 1. Division of Cardiology, - Azienda USL Toscana Nord-Ovest, Ospedale Versilia, Lido di Camaiore, Italy marialaura.canale@uslnordovest.toscana.it. 2. Division of Medical Oncology - Azienda USL Toscana Nord-Ovest, Ospedale Versilia, Lido di Camaiore, Italy. 3. Division of Cardiology, - Azienda USL Toscana Nord-Ovest, Ospedale Versilia, Lido di Camaiore, Italy. 4. Integrated Cardiology Services, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy. 5. Division of Cardiology, Ospedale Mauriziano, Turin, Italy. 6. Cardiology Unit, Oncology Department, CRO National Cancer Institute, Aviano, Italy. 7. Cardiology, Azienda USL Toscana Nord-Ovest, Ospedale Civile, Cecina, Italy. 8. Centro di Riferimento Oncologico della Basilicata IRCCS-CROB, Rionero in Vulture, Italy. 9. Division of Cardiology, Ospedale S. Martino, Belluno, Italy.
Abstract
BACKGROUND/AIM: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancer patients but their role in late cardiac toxicity is less clear. PATIENTS AND METHODS: This was a retrospective analysis of patients treated with anthracyclines (A) and/or trastuzumab (T) and a correlation with early (≤5 years) or late (>5 years) cardiac toxicity, and baseline CVRFs and CVRFs at toxicity time. RESULTS: A total of 610 patients were included, 422 with (Group A) and 188 without (Group B) baseline CVRFs. In group A toxicity incidence was 4.7% with all events during treatment or immediately after [mean onset time 0.7 years (range=0.2-1.6)]. Events rate was 3.2% in group B with all events after five years [mean time onset 6.9 years (range=5.2-7.5)]. All group B patients who developed late cardiac toxicity presented with CVRFs at the time of toxicity not reported before. CONCLUSION: CVRFs could predict late cardiac toxicity and their control should be part of the survivorship program. Copyright
BACKGROUND/AIM: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancerpatients but their role in late cardiac toxicity is less clear. PATIENTS AND METHODS: This was a retrospective analysis of patients treated with anthracyclines (A) and/or trastuzumab (T) and a correlation with early (≤5 years) or late (>5 years) cardiac toxicity, and baseline CVRFs and CVRFs at toxicity time. RESULTS: A total of 610 patients were included, 422 with (Group A) and 188 without (Group B) baseline CVRFs. In group A toxicity incidence was 4.7% with all events during treatment or immediately after [mean onset time 0.7 years (range=0.2-1.6)]. Events rate was 3.2% in group B with all events after five years [mean time onset 6.9 years (range=5.2-7.5)]. All group B patients who developed late cardiac toxicity presented with CVRFs at the time of toxicity not reported before. CONCLUSION: CVRFs could predict late cardiac toxicity and their control should be part of the survivorship program. Copyright
Authors: Maria Laura Canale; Katia Coviello; Gianluca Solarino; Jacopo Del Meglio; Federico Simonetti; Elio Venturini; Andrea Camerini; Nicola Maurea; Irma Bisceglia; Carlo Tessa; Giancarlo Casolo Journal: Front Cardiovasc Med Date: 2022-03-01
Authors: E Venturini; G Iannuzzo; A D'Andrea; M Pacileo; L Tarantini; M L Canale; M Gentile; G Vitale; F M Sarullo; R Vastarella; A Di Lorenzo; C Testa; A Parlato; C Vigorito; F Giallauria Journal: J Clin Med Date: 2020-06-10 Impact factor: 4.964